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Background
Although highly active antiretroviral therapy (HAART)
regimens have dramatically transformed treatment of
HIV infection, achieving 95% adherence to HAART
regimens is notoriously difficult. The successful creation
of an immunotherapy for infection could eliminate the
potential pitfalls associated with the necessity for long-
term adherence to drug therapy. To that end, we evalu-
ated the safety and immunogenicity of the PENNVAX®-B
vaccine, delivered with in vivo electroporation (EP) in
HIV-infected volunteers on HAART in a Phase I open-
label study.
Methods
Enrollment criteria included HIV RNA<75copies/mL,
CD4>400/µL with nadir >200/µL. Twelve eligible sub-
jects received a 4 dose series (day 0, weeks 4, 8 and 16)
of 3 mg PENNVAX®-B (consisting of SynCon® HIV
Gag, Pol, and Env immunogens) intramuscularly fol-
lowed by in vivo EP with the CELLECTRA®-5P device.
Results
All the enrolled subjects completed the immunization
schedule. The vaccine demonstrated an acceptable safety
profile and was generally well tolerated. Overall, 9 out of
12 subjects (75%) showed significant vaccine-specific
T-cell responses in the form of IFN-g ELISpot against at
least one of the three vaccine antigens (Gag, Pol, or Env)
following vaccination. Furthermore, responses were not
dominated by a single antigen, as 50% of subjects had
strong vaccine induced responses to at least 2 of the 3 anti-
gens and 3 showed vaccine-induced responses to all
3 antigens. Importantly, the ELISpot responses induced by
vaccination were predominantly CD8+T-cells, which are
considered to be paramount in clearing chronic viral infec-
tions and an important measure of the performance of a
therapeutic vaccine. Additionally, HIV-specific immune
responses were assayed by flow cytometry to measure
IFN-g production by both CD4+ and CD8+T cells as well
as co-expression of the CTL-related markers CD107a,
GranzymeB and Perforin.
Conclusion
Analysis of these data should provide more definitive
evidence of HIV-specific CTL function, which has been
implicated in control of viral replication in HIV-infected
patients.
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